These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29137299)

  • 1. Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells.
    Ohaegbulam KC; Liu W; Jeon H; Almo SC; Zang X
    Oncotarget; 2017 Oct; 8(47):82740-82753. PubMed ID: 29137299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host b7x promotes pulmonary metastasis of breast cancer.
    Abadi YM; Jeon H; Ohaegbulam KC; Scandiuzzi L; Ghosh K; Hofmeyer KA; Lee JS; Ray A; Gravekamp C; Zang X
    J Immunol; 2013 Apr; 190(7):3806-14. PubMed ID: 23455497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
    Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
    Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection.
    Hofmeyer KA; Scandiuzzi L; Ghosh K; Pirofski LA; Zang X
    J Immunol; 2012 Sep; 189(6):3054-63. PubMed ID: 22855708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7x-from bench to bedside.
    Kaur G; Janakiram M
    ESMO Open; 2019; 4(5):e000554. PubMed ID: 31555486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
    Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Checkpoint B7x (B7-H4/B7S1/VTCN1) is Over Expressed in Spontaneous Canine Bladder Cancer: The First Report and its Implications in a Preclinical Model.
    Chand D; Dhawan D; Sankin A; Ren X; Lin J; Schoenberg M; Knapp DW; Zang X
    Bladder Cancer; 2019 Jan; 5(1):63-71. PubMed ID: 30854414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
    John P; Wei Y; Liu W; Du M; Guan F; Zang X
    Trends Pharmacol Sci; 2019 Nov; 40(11):883-896. PubMed ID: 31677920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors.
    Yuan Z; Gardiner JC; Maggi EC; Huang S; Adem A; Bagdasarov S; Li G; Lee S; Slegowski D; Exarchakis A; Howe JR; Lattime EC; Zang X; Libutti SK
    Endocr Relat Cancer; 2021 Feb; 28(2):135-149. PubMed ID: 33410766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and cancer immunotherapy of the B7 family member B7x.
    Jeon H; Vigdorovich V; Garrett-Thomson SC; Janakiram M; Ramagopal UA; Abadi YM; Lee JS; Scandiuzzi L; Ohaegbulam KC; Chinai JM; Zhao R; Yao Y; Mao Y; Sparano JA; Almo SC; Zang X
    Cell Rep; 2014 Nov; 9(3):1089-98. PubMed ID: 25437562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy.
    John P; Pulanco MC; Galbo PM; Wei Y; Ohaegbulam KC; Zheng D; Zang X
    Nat Commun; 2022 May; 13(1):2506. PubMed ID: 35523809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis.
    Pawar RD; Goilav B; Xia Y; Herlitz L; Doerner J; Chalmers S; Ghosh K; Zang X; Putterman C
    Clin Exp Immunol; 2015 Feb; 179(2):329-43. PubMed ID: 25205493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression.
    Liu Y; John P; Nishitani K; Cui J; Nishimura CD; Christin JR; Couturier N; Ren X; Wei Y; Pulanco MC; Galbo PM; Zhang X; Fu W; Cui W; Bartholdy BA; Zheng D; Lauvau G; Fineberg SA; Oktay MH; Zang X; Guo W
    Dev Cell; 2023 Dec; 58(23):2700-2717.e12. PubMed ID: 37963469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells.
    Lee JS; Scandiuzzi L; Ray A; Wei J; Hofmeyer KA; Abadi YM; Loke P; Lin J; Yuan J; Serreze DV; Allison JP; Zang X
    J Immunol; 2012 Oct; 189(8):4165-74. PubMed ID: 22972920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H4(B7x)-Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients.
    Yao Y; Ye H; Qi Z; Mo L; Yue Q; Baral A; Hoon DSB; Vera JC; Heiss JD; Chen CC; Zhang J; Jin K; Wang Y; Zang X; Mao Y; Zhou L
    Clin Cancer Res; 2016 Jun; 22(11):2778-2790. PubMed ID: 27001312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8
    Li L; Han L; Sun F; Zhou J; Ohaegbulam KC; Tang X; Zang X; Steinbrecher KA; Qu Z; Xiao G
    Oncoimmunology; 2018; 7(6):e1435250. PubMed ID: 29872577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome.
    Zang X; Thompson RH; Al-Ahmadie HA; Serio AM; Reuter VE; Eastham JA; Scardino PT; Sharma P; Allison JP
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19458-63. PubMed ID: 18042703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of B7-H4/B7S1/B7x-deficient mice.
    Suh WK; Wang S; Duncan GS; Miyazaki Y; Cates E; Walker T; Gajewska BU; Deenick E; Dawicki W; Okada H; Wakeham A; Itie A; Watts TH; Ohashi PS; Jordana M; Yoshida H; Mak TW
    Mol Cell Biol; 2006 Sep; 26(17):6403-11. PubMed ID: 16914726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential targeting of B7-H4 for the treatment of cancer.
    Podojil JR; Miller SD
    Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.